Twitter | Search | |
DIA
DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate health care product development. Get started by joining our email list.
17,015
Tweets
3,008
Following
12,963
Followers
Tweets
DIA 3h
We're with Bill! Join acclaimed panelists, experienced peers and colleagues, and exhibitors innovating on the issues of today and the possibilities of tomorrow.
Reply Retweet Like
DIA 8h
Reply Retweet Like
DIA 14h
Business Relationships - how to successfully collaborate and meet regulatory requirements? Discuss with the experts:
Reply Retweet Like
DIA May 23
The author of a new book questions, in a popular New York Times op-ed, whether generic drugs are safe -- get the larger context behind the topic with DIA’s “Deep Dive” into Generic Drug Safety.
Reply Retweet Like
DIA May 22
"There is no step in the process of designing, conducting, and reporting a clinical trial that cannot be improved by introducing health literacy principles." But just what are those principles? And what is meant by health literacy? Read on:
Reply Retweet Like
DIA May 22
Learn practical tips and tricks for your daily business challenges concerning HA interactions and requirements:
Reply Retweet Like
DIA May 21
Reason to attend #6: Make the most of your conference experience with in-depth learning via Sunday's Short Courses. Get a broad overview of a topic that's new, or really hone in on a specific topic while in a small, intimate setting!
Reply Retweet Like
DIA May 21
'Each interaction with each filed product, and with each product that's approved, broadens the regulatory experience.' - Dr. Nora Ndu, Regulatory Science Co-Editor for DIA Global Forum, in 'Regulatory Science 2019 - Leading or Holding Back Innovation?'
Reply Retweet Like
DIA May 21
Do current regulations deliver on the goal of optimizing access to medicines for pediatric patients in Europe? Share your insights by submitting a poster abstract:
Reply Retweet Like
DIA May 20
Pharmacovigilance and drug safety, regulatory guidance in advertising and promotion, Health Canada policy updates and more - back-to-back events ensure you'll stay current on issues and opportunities in Canada and across the globe!
Reply Retweet Like
DIA May 20
When it comes to biosimilars and generics, what are the expectations related to the ? Join the conversation:
Reply Retweet Like
DIA May 19
What post-market safety data lessons can medical device manufacturers learn from the experiences of pharmaceutical companies? Read on in this month's Global Forum:
Reply Retweet Like
DIA May 18
Availability of generic drug products has many benefits, but scientific & regulatory complexity can lengthen the route to better, faster patient outcomes. Enter: "Scenarios for Complex Generic Drug Development: FDA and Pre-ANDA Interaction" in San Diego!
Reply Retweet Like
DIA May 17
Billions of dollars are spent annually on cancer drug development, yet effective treatments for many types of cancers remain as elusive as ever. What are the chances of getting a cancer drug approved?
Reply Retweet Like
DIA May 17
What impact might Brexit have on the UK and EU therapeutics sector - and though far from certain, what might a 'no-deal Brexit' mean for Asia-Pacific markets? Read on in DIA Global Forum:
Reply Retweet Like
DIA May 17
Thank you to our talented faculty for a successful training week in Amsterdam. Join Gaby Danan and several regulators (7) and industry experts in June for the Pharmacovigilance Strategies Workshop. View all speakers:
Reply Retweet Like
DIA May 16
Innovation battles complexity to provide access in response to demands in Asia. Check out highlights of the second DIA-CoRE Singapore Annual Meeting:
Reply Retweet Like
DIA May 16
Interested in an overview of the Framework in Europe? Learn from the experts:
Reply Retweet Like
DIA May 15
What does the Future of Healthcare Evidence look like? Gain valuable insights into data sharing and usage, evidence generation, regulatory and access frameworks and more. Learn more:
Reply Retweet Like
DIA May 14
DIA members are active change-makers from academia, patient groups, regulatory fields, research and development, payers, clinical development, medical affairs & more. Grow your career, skills and network...and help focus on the future of health.
Reply Retweet Like